Koutsikos John, Angelidis George, Zafeirakis Athanasios, Mamarelis Ioannis, Vogiatzis Merkourios, Ilia Eliverta, Lazaridis Kyriakos, Demakopoulos Nikolaos
Department of Nuclear Medicine Army Share Fund Hospital (417 NIMTS) Athens, Greece.
Hell J Nucl Med. 2017 Sep-Dec;20(3):232-236. doi: 10.1967/s002449910607. Epub 2017 Nov 27.
MPI can provide valuable information in the investigation of patients with known or suspected coronary artery disease. The stress component of the studies can be conducted with regadenoson, which was approved for clinical use in Greece in 2016. We investigated the performance and safety profile of regadenoson MPI based on our 7 months institutional experience.
We studied 96 consecutive patients (59 males, 37 females, mean age 70.35y.o, range: 46-87y.o.) referred to our department for a clinically indicated MPI study with pharmacological stress. Eleven patients suffered from chronic obstructive pulmonary disease. Patients underwent regadenoson stress test, combined with both stress and rest imaging. Data on the symptoms and electrocardiographic changes due to regadenoson administration were recorded. Symptoms were graded as 1-mild: a symptom that did not distress the patient, 2-moderate: a symptom that distressed the patient but it was self-limiting, or 3-severe: a symptom that distressed the patient requiring medical intervention.
Regadenoson-related symptoms were reported in 56 patients and were: dyspnea, discomfort, dizziness, chest pain, epigastric pain, neck pain, headache, flushing, nausea, heartburn, weakness, and upper limbs numbness. The severity of symptoms was recorded as grade 1 in 30 patients, grade 2 in 25 patients, and grade 3 in 1 patient. Two or more different symptoms were reported in 28 patients. Ischemic electrocardiographic changes and arrhythmias were observed in 8 patients.
Our findings support previously published data indicating the optimal safety profile of regadenoson MPI, even in the group of patients suffering from chronic obstructive pulmonary disease.
心肌灌注成像（MPI）在已知或疑似冠心病患者的检查中可提供有价值的信息。该研究的负荷部分可使用瑞加德松进行，瑞加德松于2016年在希腊获批用于临床。基于我们7个月的机构经验，我们对瑞加德松MPI的性能和安全性进行了研究。
我们研究了96例连续患者（59例男性，37例女性，平均年龄70.35岁，范围：46 - 87岁），这些患者因临床指征需进行药物负荷的MPI研究而转诊至我科。11例患者患有慢性阻塞性肺疾病。患者接受瑞加德松负荷试验，并结合负荷和静息成像。记录因注射瑞加德松引起的症状和心电图变化数据。症状分为1级 - 轻度：未使患者感到困扰的症状；2级 - 中度：使患者感到困扰但为自限性的症状；或3级 - 重度：使患者感到困扰且需要医疗干预的症状。
56例患者报告了与瑞加德松相关的症状，包括：呼吸困难、不适、头晕、胸痛、上腹部疼痛、颈部疼痛、头痛、潮红、恶心、烧心、虚弱和上肢麻木。症状严重程度记录为1级的有30例患者，2级的有25例患者，3级的有1例患者。28例患者报告了两种或更多不同症状。8例患者观察到缺血性心电图变化和心律失常。
我们的研究结果支持先前发表的数据，表明瑞加德松MPI具有最佳安全性，即使在患有慢性阻塞性肺疾病的患者群体中也是如此。
